Phenytoin Dosing in Obese Patients: Two Case Reports
- 1 September 1988
- journal article
- research article
- Published by SAGE Publications in Drug Intelligence & Clinical Pharmacy
- Vol. 22 (9) , 708-710
- https://doi.org/10.1177/106002808802200915
Abstract
Phenytoin is used extensively in the treatment of various forms of epilepsy, and remains the drug of choice in partial and generalized tonic-clonic seizures. Because it demonstrates saturable, Michaelis-Menten pharmacokinetics, dosing of phenytoin within the therapeutic range can be very challenging, especially so in obese patients. We present case reports of two obese patients each requiring very large doses of phenytoin sodium (1000 mg/d) to sustain therapeutic serum concentrations and seizure control. There are very few reports in the literature regarding phenytoin pharmacokinetic changes in the obese. We can only theorize possible changes in these parameters. Further investigation in the form of controlled research trials need to be performed before final dosage recommendations can be given.Keywords
This publication has 6 references indexed in Scilit:
- Phenytoin Disposition in ObesityArchives of Neurology, 1985
- Serum protein binding and the role of increased alpha 1‐acid glycoprotein in moderately obese male subjects.British Journal of Clinical Pharmacology, 1984
- Serum alpha 1‐acid glycoprotein and the binding of drugs in obesity.British Journal of Clinical Pharmacology, 1983
- Pharmacokinetics of Drugs in ObesityClinical Pharmacokinetics, 1982
- Effect of age, height, weight and sex on serum phenytoin concentration in epileptic patients.British Journal of Clinical Pharmacology, 1975
- Effects of Age, Sex, Obesity, and Pregnancy on Plasma Diphenylhydantoin LevelsEpilepsia, 1974